<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Downey Obesity Report &#187; MANAGING OBESITY</title>
	<atom:link href="http://www.downeyobesityreport.com/category/managing-obesity/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.downeyobesityreport.com</link>
	<description>No other human condition combines obesity&#039;s prevalence and prejudice; sickness and stigma; death and discrimination.</description>
	<lastBuildDate>Mon, 06 Feb 2012 22:07:48 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1</generator>
		<item>
		<title>FDA Approves Once Weekly Drug for Diabetes; Shows Weight Loss</title>
		<link>http://www.downeyobesityreport.com/2012/01/fda-approves-once-weekly-drug-for-diabetes-shows-weight-loss/</link>
		<comments>http://www.downeyobesityreport.com/2012/01/fda-approves-once-weekly-drug-for-diabetes-shows-weight-loss/#comments</comments>
		<pubDate>Sat, 28 Jan 2012 17:32:05 +0000</pubDate>
		<dc:creator>MorganDowney</dc:creator>
				<category><![CDATA[DAILY DOWNEY]]></category>
		<category><![CDATA[Drug Therapy]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[A1c testing]]></category>
		<category><![CDATA[adolescents]]></category>
		<category><![CDATA[children]]></category>
		<category><![CDATA[extreme obesity]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[Type 2 diabetes]]></category>
		<category><![CDATA[weight loss]]></category>

		<guid isPermaLink="false">http://www.downeyobesityreport.com/?p=2822</guid>
		<description><![CDATA[The Food and Drug Administration has approved Amylin Pharmaceutical’s Bydureon for thetreatment of type 2 diabetes. This is the first once-weekly treatment for type 2 diabetes. It is hoped that this feature will lead to higher adherence to the treatment regimen, although as with Byetta, it is injectable. The drug is exenatide, a GLP-1 receptor [...]]]></description>
		<wfw:commentRss>http://www.downeyobesityreport.com/2012/01/fda-approves-once-weekly-drug-for-diabetes-shows-weight-loss/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NIH Recommends A1c Testing</title>
		<link>http://www.downeyobesityreport.com/2012/01/nih-recommends-a1c-testing/</link>
		<comments>http://www.downeyobesityreport.com/2012/01/nih-recommends-a1c-testing/#comments</comments>
		<pubDate>Thu, 26 Jan 2012 22:33:38 +0000</pubDate>
		<dc:creator>MorganDowney</dc:creator>
				<category><![CDATA[DAILY DOWNEY]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Federal Government]]></category>
		<category><![CDATA[MANAGING OBESITY]]></category>
		<category><![CDATA[A1c testing]]></category>
		<category><![CDATA[National Institutes of Health]]></category>
		<category><![CDATA[Type 2 diabetes]]></category>

		<guid isPermaLink="false">http://www.downeyobesityreport.com/?p=2802</guid>
		<description><![CDATA[The National Institutes of Health has come out for expanded A1c testing. Their press release and fact sheet point out that the A1c test does not require fasting and helps identify diabetes and pre-diabetes. They recommend testing of anyone 45 years old or younger than 45 are overweight, inactive or have at least one risk [...]]]></description>
		<wfw:commentRss>http://www.downeyobesityreport.com/2012/01/nih-recommends-a1c-testing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bariatric Surgery for Teens on the Rise</title>
		<link>http://www.downeyobesityreport.com/2011/12/bariatric-surgery-for-teens-on-the-rise/</link>
		<comments>http://www.downeyobesityreport.com/2011/12/bariatric-surgery-for-teens-on-the-rise/#comments</comments>
		<pubDate>Tue, 27 Dec 2011 23:42:02 +0000</pubDate>
		<dc:creator>MorganDowney</dc:creator>
				<category><![CDATA[Bariatric Surgery]]></category>
		<category><![CDATA[DAILY DOWNEY]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[adolescents]]></category>

		<guid isPermaLink="false">http://www.downeyobesityreport.com/?p=2774</guid>
		<description><![CDATA[A new study shows a dramatic increase in bariatric surgery for adolescents. The procedures have changed with an increase in gastric banding and a decrease in gastric bypass. Side effects and mortality remain small in this study of academic medical centers. Increasing utilization of laparoscopic gastric bandi&#8230; [Am Surg. 2011] &#8211; PubMed &#8211; NCBI]]></description>
		<wfw:commentRss>http://www.downeyobesityreport.com/2011/12/bariatric-surgery-for-teens-on-the-rise/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Allergan Slapped on Marketing Lap-Band</title>
		<link>http://www.downeyobesityreport.com/2011/12/allergan-slapped-on-marketing-lap-band/</link>
		<comments>http://www.downeyobesityreport.com/2011/12/allergan-slapped-on-marketing-lap-band/#comments</comments>
		<pubDate>Tue, 27 Dec 2011 23:23:02 +0000</pubDate>
		<dc:creator>MorganDowney</dc:creator>
				<category><![CDATA[Bariatric Surgery]]></category>
		<category><![CDATA[DAILY DOWNEY]]></category>
		<category><![CDATA[Federal Government]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[Lap-Band]]></category>
		<category><![CDATA[marketing]]></category>

		<guid isPermaLink="false">http://www.downeyobesityreport.com/?p=2770</guid>
		<description><![CDATA[After the FDA slapped Allergan for the marketing campaign of one of its vendors,  2011 &#62; 1 800 Get Thin LLC 12/12/11, the Los Angeles Times took on Allergan to do step up to the real work of corporate responsibility. Lap-Band maker needs to step up &#8211; Los Angeles Times. A lot of health care [...]]]></description>
		<wfw:commentRss>http://www.downeyobesityreport.com/2011/12/allergan-slapped-on-marketing-lap-band/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vivus Inc. Announces Date for FDA AdCom; results of birth defect study</title>
		<link>http://www.downeyobesityreport.com/2011/12/vivus-inc-announces-date-for-fda-adcom-results-of-birth-defect-study/</link>
		<comments>http://www.downeyobesityreport.com/2011/12/vivus-inc-announces-date-for-fda-adcom-results-of-birth-defect-study/#comments</comments>
		<pubDate>Fri, 23 Dec 2011 21:07:32 +0000</pubDate>
		<dc:creator>MorganDowney</dc:creator>
				<category><![CDATA[DAILY DOWNEY]]></category>
		<category><![CDATA[Drug Therapy]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Federal Government]]></category>
		<category><![CDATA[birth defects]]></category>
		<category><![CDATA[Qnexa]]></category>
		<category><![CDATA[Topiramate]]></category>
		<category><![CDATA[Vivus Inc]]></category>

		<guid isPermaLink="false">http://www.downeyobesityreport.com/?p=2724</guid>
		<description><![CDATA[Vivus Inc. has announced that the FDA will hold an   Advisory Committee meeting on February 22, 2012 for review of the obesity treatment, Qnexa. VIVUS, Inc. &#8211; VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of ObesityTwo days ago, Vivus Inc. released resulted of the FORTRESS study.  The study looked [...]]]></description>
		<wfw:commentRss>http://www.downeyobesityreport.com/2011/12/vivus-inc-announces-date-for-fda-adcom-results-of-birth-defect-study/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Genetics and Treatments</title>
		<link>http://www.downeyobesityreport.com/2011/12/genetics-and-treatments/</link>
		<comments>http://www.downeyobesityreport.com/2011/12/genetics-and-treatments/#comments</comments>
		<pubDate>Tue, 20 Dec 2011 23:43:05 +0000</pubDate>
		<dc:creator>MorganDowney</dc:creator>
				<category><![CDATA[DAILY DOWNEY]]></category>
		<category><![CDATA[Drug Therapy]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Genetic Basis of Obesity]]></category>
		<category><![CDATA[MANAGING OBESITY]]></category>
		<category><![CDATA[behavioral intervention]]></category>
		<category><![CDATA[diabetes prevention program]]></category>
		<category><![CDATA[metformin]]></category>

		<guid isPermaLink="false">http://www.downeyobesityreport.com/?p=2707</guid>
		<description><![CDATA[The Diabetes Prevention Program (DPP) is regarded as a hallmark of behavioral intervention in the treatment of adult obesity. Now comes a paper from the DPP Study Group, as well as drug therapy via metformin. It recognizes that genetic factors affect the success of participants in achieving and maintain weight loss. Genetic Predictors of Weight [...]]]></description>
		<wfw:commentRss>http://www.downeyobesityreport.com/2011/12/genetics-and-treatments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Study Raises Prospect of Qnexa Approval</title>
		<link>http://www.downeyobesityreport.com/2011/12/study-raises-prospect-of-qnexa-approval/</link>
		<comments>http://www.downeyobesityreport.com/2011/12/study-raises-prospect-of-qnexa-approval/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 17:56:41 +0000</pubDate>
		<dc:creator>MorganDowney</dc:creator>
				<category><![CDATA[DAILY DOWNEY]]></category>
		<category><![CDATA[Drug Therapy]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Federal Government]]></category>
		<category><![CDATA[birth defects]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[Qnexa]]></category>
		<category><![CDATA[Vivus Inc]]></category>

		<guid isPermaLink="false">http://www.downeyobesityreport.com/?p=2634</guid>
		<description><![CDATA[A study published December 7, 2011in the American Journal of Clinical Nutrition provides two-year data on the safety and effectiveness of Vivus Inc.’s drug candidate, Qnexa in patients with cardiometabolic disease. Qnexa is a combination drug composed of phentermine and topiramate. It was tested in two doses among 676 subjects. Changes in weight were -1.8% [...]]]></description>
		<wfw:commentRss>http://www.downeyobesityreport.com/2011/12/study-raises-prospect-of-qnexa-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bariatric Surgery for Teens</title>
		<link>http://www.downeyobesityreport.com/2011/12/bariatric-surgery-for-teens/</link>
		<comments>http://www.downeyobesityreport.com/2011/12/bariatric-surgery-for-teens/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 15:00:43 +0000</pubDate>
		<dc:creator>MorganDowney</dc:creator>
				<category><![CDATA[Bariatric Surgery]]></category>
		<category><![CDATA[DAILY DOWNEY]]></category>
		<category><![CDATA[Featured]]></category>

		<guid isPermaLink="false">http://www.downeyobesityreport.com/?p=2594</guid>
		<description><![CDATA[Washington Post article shows teens can benefit from bariatric surgery but access is limited by insurance companies. Bariatric surgery may help teens, but insurers often exclude them &#8211; The Washington Post]]></description>
		<wfw:commentRss>http://www.downeyobesityreport.com/2011/12/bariatric-surgery-for-teens/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Consumer Alert &#8211; HCG hormone</title>
		<link>http://www.downeyobesityreport.com/2011/12/consumer-alert-hcg-hormone/</link>
		<comments>http://www.downeyobesityreport.com/2011/12/consumer-alert-hcg-hormone/#comments</comments>
		<pubDate>Tue, 06 Dec 2011 20:24:19 +0000</pubDate>
		<dc:creator>MorganDowney</dc:creator>
				<category><![CDATA[Consumer Protection]]></category>
		<category><![CDATA[DAILY DOWNEY]]></category>
		<category><![CDATA[Federal Government]]></category>
		<category><![CDATA[Federal Trade Commission]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[HCG hormone]]></category>

		<guid isPermaLink="false">http://www.downeyobesityreport.com/?p=2460</guid>
		<description><![CDATA[The Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) have issued warning letters on HCG “homeopathic” products sold over-the-counter for weight loss.  HCG or human chorionic gonadotropin is a hormone produced by the human placenta and found in the urine of pregnant women. It is approved as an injectable prescription drug for [...]]]></description>
		<wfw:commentRss>http://www.downeyobesityreport.com/2011/12/consumer-alert-hcg-hormone/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Effects of Childhood Obesity Can be Reversed</title>
		<link>http://www.downeyobesityreport.com/2011/11/effects-of-childhood-obesity-can-be-reversed/</link>
		<comments>http://www.downeyobesityreport.com/2011/11/effects-of-childhood-obesity-can-be-reversed/#comments</comments>
		<pubDate>Thu, 17 Nov 2011 17:19:57 +0000</pubDate>
		<dc:creator>MorganDowney</dc:creator>
				<category><![CDATA[Childhood Obesity]]></category>
		<category><![CDATA[DAILY DOWNEY]]></category>
		<category><![CDATA[Effects of Weight Loss]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[NEWS]]></category>
		<category><![CDATA[adulthood]]></category>
		<category><![CDATA[atherosclerosis]]></category>
		<category><![CDATA[hypertension]]></category>
		<category><![CDATA[Type 2 diabetes]]></category>

		<guid isPermaLink="false">http://www.downeyobesityreport.com/?p=2297</guid>
		<description><![CDATA[An analysis (published today in the New England Journal of Medicine) of over 6,000 subjects followed for 23 years found persons who were obese in childhood had high risk of type 2 diabetes, hypertension, elevated low-density and high-density cholesterol, triglyceride levels as well as carotid-artery atherosclerosis compared to persons who were never obese. However, persons [...]]]></description>
		<wfw:commentRss>http://www.downeyobesityreport.com/2011/11/effects-of-childhood-obesity-can-be-reversed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

